Home
TEVA
TEVA News

Latest Teva Pharmaceutical Industries Limited (TEVA) News on September 8, 2025

Teva (NYSE:TEVA) Valuation in Focus After FDA Approval and U.S. Launch of Generic Saxenda

Simply Wall St.

2 days ago

Teva (NYSE:TEVA) Valuation in Focus After FDA Approval and U.S. Launch of Generic Saxenda

TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?

Zacks

4 days ago

TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?

Anti-Parkinson's Drugs Global Market Research Report 2025-2030 | $9.2 Bn Opportunities Driven by Increased Awareness in Emerging Countries and a Robust Pipeline of Innovations

GlobeNewswire

4 days ago

Anti-Parkinson's Drugs Global Market Research Report 2025-2030 | $9.2 Bn Opportunities Driven by Increased Awareness in Emerging Countries and a Robust Pipeline of Innovations

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

GlobeNewswire

6 days ago

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

Teva Pharmaceutical Industries (TEVA) Announces the FDA Approval and U.S. Launch of Generic Saxenda

Insider Monkey

8 days ago

Teva Pharmaceutical Industries (TEVA) Announces the FDA Approval and U.S. Launch of Generic Saxenda

Did FDA Approval of Generic Saxenda Just Shift Teva's (TEVA) Investment Narrative?

Simply Wall St.

9 days ago

Did FDA Approval of Generic Saxenda Just Shift Teva's (TEVA) Investment Narrative?

Teva brings first generic GLP-1 to US market with Saxenda copycat approval

Pharmaceutical Technology

10 days ago

Teva brings first generic GLP-1 to US market with Saxenda copycat approval

Teva Pharmaceutical Industries Limited (TEVA) Gains FDA Nod for Pediatric Migraine Drug AJOVY

Insider Monkey

10 days ago

Teva Pharmaceutical Industries Limited (TEVA) Gains FDA Nod for Pediatric Migraine Drug AJOVY

FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk

Investor's Business Daily

11 days ago

FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk

Deckers Outdoor (DECK) Sees 12% Rise in Share Price Over Past Week

Simply Wall St.

11 days ago

Deckers Outdoor (DECK) Sees 12% Rise in Share Price Over Past Week

MT Newswires

11 days ago

Teva Pharmaceuticals Launches Generic Weight Loss Injection Saxenda; Shares Up Pre-Bell

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

GlobeNewswire

11 days ago

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

MT Newswires

14 days ago

Catalyst Pharmaceuticals Says Settlement Reached With Lupin Pharmaceuticals in Firdapse Patent Litigation

Deckers Outdoor (DECK): Assessing Valuation After New Teva Launches and Continued Earnings Momentum

Simply Wall St.

14 days ago

Deckers Outdoor (DECK): Assessing Valuation After New Teva Launches and Continued Earnings Momentum

Simply Wall St.

17 days ago

Will Teva’s Designer Collaboration and New Collection Signal a Brand Evolution for Deckers (DECK)?

CalPrivate Bank Appoints Angel Martinez to the CalPrivate Bank Board

GlobeNewswire

18 days ago

CalPrivate Bank Appoints Angel Martinez to the CalPrivate Bank Board

Latest Fed cut signals, pharma relief rally, Apple TV+ price hike

Yahoo Finance Video

18 days ago

Latest Fed cut signals, pharma relief rally, Apple TV+ price hike

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

GlobeNewswire

18 days ago

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

US-EU trade deal impacts on pharma industry more 'manageable' than expected

Yahoo Finance

18 days ago

US-EU trade deal impacts on pharma industry more 'manageable' than expected

Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?

Zacks

18 days ago

Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?

Teva Debuts Autumn Winter 2025 Collection Inspired By "For Playground Earth"

Business Wire

20 days ago

Teva Debuts Autumn Winter 2025 Collection Inspired By "For Playground Earth"

Teva Releases Q2 2025 Aide Memoire

GlobeNewswire

2 months ago

Teva Releases Q2 2025 Aide Memoire

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

Insider Monkey

2 months ago

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

GlobeNewswire

2 months ago

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?

Motley Fool

2 months ago

Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?

Teva reports final analysis of migraine prevention trial of Ajovy

Clinical Trials Arena

2 months ago

Teva reports final analysis of migraine prevention trial of Ajovy

Goldman Sachs Starts Teva Pharma (TEVA) at Buy on Branded Drug Growth

Insider Monkey

2 months ago

Goldman Sachs Starts Teva Pharma (TEVA) at Buy on Branded Drug Growth

J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?

Zacks

3 months ago

J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

GlobeNewswire

3 months ago

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy

Zacks

3 months ago

Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy

Generic Drugmakers Resist Trump’s Calls for More U.S. Manufacturing

The Wall Street Journal

3 months ago

Generic Drugmakers Resist Trump’s Calls for More U.S. Manufacturing

Teva, Fosun Pharma partner to develop TEV-56278

TipRanks

3 months ago

Teva, Fosun Pharma partner to develop TEV-56278

Teva to collaborate with Fosun Pharma for TEV-56278

Pharmaceutical Technology

3 months ago

Teva to collaborate with Fosun Pharma for TEV-56278

MT Newswires

3 months ago

Teva Pharmaceutical Industries Insider Sold Shares Worth $952,464, According to a Recent SEC Filing

MT Newswires

3 months ago

Teva Pharmaceutical, Shanghai Fosun Partner to Develop Cancer Treatment Drug

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

GlobeNewswire

3 months ago

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters

Motley Fool

3 months ago

Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters

Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris

Zacks

3 months ago

Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris

3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats

Zacks

3 months ago

3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats

CrowdStrike and McDonald’s downgraded: Wall Street’s top analyst calls

TipRanks

3 months ago

CrowdStrike and McDonald’s downgraded: Wall Street’s top analyst calls

Investing.com

3 months ago

Goldman Sachs initiates coverage on generic drugmakers, sees upside in Teva and Am

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

GlobeNewswire

3 months ago

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

MT Newswires

3 months ago

Teva Pharmaceutical Industries Raises Pool Tender Offer, Reports Early Tender Results

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

GlobeNewswire

3 months ago

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

Morningstar Research

3 months ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

GlobeNewswire

3 months ago

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

GlobeNewswire

3 months ago

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

Morningstar Research

3 months ago

Analyst Report: Teva Pharmaceutical Industries Limited

Morningstar Research

3 months ago

Analyst Report: Teva Pharmaceutical Industries Limited

Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target

Insider Monkey

3 months ago

Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

GlobeNewswire

3 months ago

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate

Zacks

3 months ago

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate

MT Newswires

3 months ago

Truist Securities Initiates Teva Pharmaceutical Industries at Buy With $25 Price Target

Billionaire Stanley Druckenmiller Just Sold One of Wall Street's Hottest Stock-Split Stocks and Is Piling Into a Promising Drugmaker Instead

Motley Fool

3 months ago

Billionaire Stanley Druckenmiller Just Sold One of Wall Street's Hottest Stock-Split Stocks and Is Piling Into a Promising Drugmaker Instead

Teva Pharmaceutical Industries Limited (TEVA) Wins FDA Fast Track for Celiac Disease Drug TEV-53408

Insider Monkey

3 months ago

Teva Pharmaceutical Industries Limited (TEVA) Wins FDA Fast Track for Celiac Disease Drug TEV-53408

MT Newswires

3 months ago

Teva Pharmaceutical Receives FDA Fast Track Designation for Drug to Treat Celiac Disease

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

GlobeNewswire

3 months ago

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

GlobeNewswire

3 months ago

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

Why Is Teva Stock Trading Higher On Tuesday?

Benzinga

3 months ago

Why Is Teva Stock Trading Higher On Tuesday?

TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock?

Zacks

3 months ago

TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock?

MT Newswires

3 months ago

Teva Pharmaceutical Industries Begins Preclinical Testing of Inflammation Drug BD9

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

GlobeNewswire

3 months ago

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

Regulatory Shake-Up Led to the Sell Off in Teva Pharmaceutical Industries Limited (TEVA)

Insider Monkey

3 months ago

Regulatory Shake-Up Led to the Sell Off in Teva Pharmaceutical Industries Limited (TEVA)

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

GlobeNewswire

4 months ago

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

Teva Pharmaceutical Industries (NYSE:TEVA) Upsizes Senior Notes Offering to US$2.3 Billion

Simply Wall St.

4 months ago

Teva Pharmaceutical Industries (NYSE:TEVA) Upsizes Senior Notes Offering to US$2.3 Billion

MT Newswires

4 months ago

Teva Pharmaceutical Prices Upsized $2.3 Billion Notes Offering

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

GlobeNewswire

4 months ago

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

GlobeNewswire

4 months ago

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

MT Newswires

4 months ago

Teva Pharmaceutical Plans Issuance of $2 Billion Equivalent of Senior Notes

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

GlobeNewswire

4 months ago

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

GlobeNewswire

4 months ago

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

GlobeNewswire

4 months ago

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

Insider Monkey

4 months ago

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks

4 months ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Teva Pharmaceutical Industries Limited (TEVA): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying

Insider Monkey

4 months ago

Teva Pharmaceutical Industries Limited (TEVA): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying

Teva's 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy

ACCESS Newswire

4 months ago

Teva's 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy

Argus Research

4 months ago

Analyst Report: Teva Phar Inds Lt

Argus Research

4 months ago

Market Update: TEVA, ODFL, UBER, NET

Argus Research

4 months ago

Daily – Vickers Top Buyers & Sellers for 05/13/2025

Why Teva Pharmaceuticals Stock Blasted 6% Higher Today

Motley Fool

4 months ago

Why Teva Pharmaceuticals Stock Blasted 6% Higher Today

MT Newswires

4 months ago

Teva Pharmaceutical Industries Insider Sold Shares Worth $6,097,304, According to a Recent SEC Filing

Teva's Bold $700M Gamble: Will It Be Enough to Rescue Its Plummeting Stock?

GuruFocus.com

4 months ago

Teva's Bold $700M Gamble: Will It Be Enough to Rescue Its Plummeting Stock?

MT Newswires

4 months ago

Teva Pharmaceutical Industries Shares Rise After JPMorgan Upgrades Rating

MT Newswires

4 months ago

JPMorgan Upgrades Teva Pharmaceutical Industries to Overweight From Neutral, Adjusts Price Target to $23 From $21

Morningstar Research

4 months ago

Analyst Report: Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited (TEVA): Among Billionaire Larry Robbins’ Stock Picks with Huge Upside Potential

Insider Monkey

4 months ago

Teva Pharmaceutical Industries Limited (TEVA): Among Billionaire Larry Robbins’ Stock Picks with Huge Upside Potential

Teva Pharmaceutical Industries (NYSE:TEVA) Settles Class-Action Lawsuit For US$2 Million

Simply Wall St.

4 months ago

Teva Pharmaceutical Industries (NYSE:TEVA) Settles Class-Action Lawsuit For US$2 Million

Morningstar Research

4 months ago

Analyst Report: Teva Pharmaceutical Industries Limited

TEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock Up

Zacks

4 months ago

TEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock Up

Teva Pharmaceutical Industries First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

4 months ago

Teva Pharmaceutical Industries First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Teva Pharmaceutical Industries Ltd (TEVA) Q1 2025 Earnings Call Highlights: Strong Growth in ...

GuruFocus.com

4 months ago

Teva Pharmaceutical Industries Ltd (TEVA) Q1 2025 Earnings Call Highlights: Strong Growth in ...

Why Teva Pharmaceutical Industries Limited (TEVA) Skyrocketed On Wednesday

Insider Monkey

4 months ago

Why Teva Pharmaceutical Industries Limited (TEVA) Skyrocketed On Wednesday

Teva Stock Jumps On Outlook. CEO Touts 'Real Clarity' On Future Profits.

Investor's Business Daily

4 months ago

Teva Stock Jumps On Outlook. CEO Touts 'Real Clarity' On Future Profits.

Why Teva Pharmaceutical Stock Is Soaring Today

Motley Fool

4 months ago

Why Teva Pharmaceutical Stock Is Soaring Today

MT Newswires

4 months ago

Sector Update: Health Care Stocks Gain Wednesday Afternoon

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says

Barrons.com

4 months ago

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says

MT Newswires

4 months ago

Sector Update: Health Care Stocks Advance Pre-Bell Wednesday

Teva Surges On Profit Guidance Boost Despite A Mixed First-Quarter Report

Investor's Business Daily

4 months ago

Teva Surges On Profit Guidance Boost Despite A Mixed First-Quarter Report

MT Newswires

4 months ago

Teva Pharmaceutical's Q1 Non-GAAP Earnings, Revenue Rise; 2025 Guidance Updated

Teva Pharm first-quarter profit rise tops estimates

Reuters

4 months ago

Teva Pharm first-quarter profit rise tops estimates

Share on Social Networks: